Rapid Micro Biosystems' Q3 revenue misses estimates, withdraws FY outlook
RPID•
RPID•Rapid Micro Biosystems' third-quarter revenue rose 22% year over year to $9.50 million, below the $10 million estimate, while gross margin reached a record 25%. The company withdrew its 2026 outlook due to its pending acquisition by Merck KGaA.
Rapid Micro Biosystems reported third-quarter revenue of $9.50 million, up 22% year over year but below the $10 million consensus estimate. The company reported a loss per share of $0.23 and operating expenses of $13 million.
Revenue growth was driven by placements of seven Growth Direct systems and completion of 12 customer validations. Gross margin rose 16 percentage points year over year to a record 25%, which the company attributed to margin expansion initiatives, including higher product and service gross margins. The company withdrew its full-year 2026 guidance due to its pending acquisition by Merck KGaA.